This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krueger, W. A.
Right arrow Articles by Schroeder, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krueger, W. A.
Right arrow Articles by Schroeder, T. H.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 2008, p. 817-820, Vol. 46, No. 2
0095-1137/08/$08.00+0     doi:10.1128/JCM.01340-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

CASE REPORT

Treatment with Tigecycline of Recurrent Urosepsis Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli{triangledown}

Wolfgang A. Krueger,1* Volkhard A. J. Kempf,2 Manou Peiffer,1 Udo Nagele,3 Klaus E. Unertl,1 and Torsten H. Schroeder1

Department of Anesthesiology and Intensive Care Medicine,1 Department of Urology, Tübingen University Hospital, Hoppe-Seyler-Str. 3,3 Institute for Medical Microbiology and Hygiene, Tübingen University Hospital, Elfriede-Aulhorn-Str. 6, 72076 Tübingen, Germany2

Received 4 July 2007/ Returned for modification 5 November 2007/ Accepted 4 December 2007

A 25-year-old female was admitted to our intensive care unit with septic shock and multiorgan failure caused by extended-spectrum β-lactamase-producing Escherichia coli originating from the right renal pelvis. A 16-day course of treatment with meropenem reversed the septic condition, but the infection recurred thereafter. The patient recovered fully after therapy was changed to tigecycline.

* Corresponding author. Mailing address: Tübingen University Hospital, Department of Anesthesiology and Intensive Care Medicine, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany. Phone: 49-7071-298-6622. Fax: 49-7071-29-5533. E-mail: wolfgang.krueger{at}uni-tuebingen.de

{triangledown} Published ahead of print on 12 December 2007.

Journal of Clinical Microbiology, February 2008, p. 817-820, Vol. 46, No. 2
0095-1137/08/$08.00+0     doi:10.1128/JCM.01340-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Cunha, B. A. (2009). Pharmacokinetic Considerations regarding Tigecycline for Multidrug-Resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii Urosepsis. J. Clin. Microbiol. 47: 1613-1613 [Full Text]  
  • Kelesidis, T., Karageorgopoulos, D. E., Kelesidis, I., Falagas, M. E. (2008). Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62: 895-904 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»